Molecular mechanisms of drug resistance in clinical Candida species isolated from tunisian hospitals

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3182-3193

  Eddouzi, Jamel ^a,b   Parker, Josie E ^c   Vale Silva, Luis A ^a   Coste, Alix ^a   Ischer, Françoise ^a   Kelly, Steve ^c   Manai, Mohamed ^b   Sanglard, Dominique ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

14ALPHA METHYL ERGOSTA 8,24(28) DIEN 3ALPHA,6BETA DIOL; 14ALPHA METHYL FECOSTEROL; AMPHOTERICIN B; BREFELDIN A; CASPOFUNGIN; ERGOSTEROL; FLUCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEOTIDE; POLYENE; PROTEIN ERG 11; PYRROLE; STEROL DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA TROPICALIS; CONTROLLED STUDY; CROSS RESISTANCE; DNA SEQUENCE; FUNGUS ISOLATION; GAIN OF FUNCTION MUTATION; HOSPITAL; MASS FRAGMENTOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TUNISIA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; BASE SEQUENCE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CANDIDIASIS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; ERGOSTEROL; FLUCONAZOLE; FUNGAL PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; P-GLYCOPROTEIN; POLYENES; PYRIMIDINES; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SEQUENCE ANALYSIS, DNA; TRIAZOLES; TUNISIA;

EID: 84879018308     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00555-13     Document Type: Article

References (54)

1. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
2. Ohkubo T, Sugawara Y, Takayama T, Kokudo N, Makuuchi M. 2012. The risk factors of fungal infection in living-donor liver transplantations. J. Hepatobiliary Pancreat. Sci. 19:382-388.
3. Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, Morrissey CO, Chen SC. 2010. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J. Antimicrob. Chemother. 65:1042-1051.
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317. (Pubitemid 39050477)
5. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. 2005. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. 43:5425-5427. (Pubitemid 41612308)
6. Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, Tiraboschi N, Nagy E, Gibbs DL. 2005. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J. Clin. Microbiol. 43:5848-5859. (Pubitemid 43100628)
7. Kothavade RJ, Kura MM, Valand AG, Panthaki MH. 2010. Candida tropicalis: its prevalence, pathogenicity, and increasing resistance to fluconazole. J. Med. Microbiol. 59:873-880.
8. Chai YA, Wang Y, Khoo AL, Chan FY, Chow C, Kumarasinghe G, Singh K, Tambyah PA. 2007. Predominance of Candida tropicalis bloodstream infections in a Singapore teaching hospital. Med. Mycol. 45:435-439. (Pubitemid 47190129)
9. Yang YL, Cheng MF, Wang CW, Wang AH, Cheng WT, Lo HJ, Hospitals T. 2010. The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from sterile sites in Taiwan. Med. Mycol. 48:328-334.
10. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J. 1999. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob. Agents Chemother. 43:2753-2765. (Pubitemid 29519560)
11. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL. 2004. In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob. Agents Chemother. 48:3107-3111. (Pubitemid 38989181)
12. Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42:3065-3072. (Pubitemid 28553719)
13. Warrilow AG, Martel CM, Parker JE, Melo N, Lamb DC, Nes WD, Kelly DE, Kelly SL. 2010. Azole binding properties of Candida albicans sterol 14-α demethylase (CaCYP51). Antimicrob. Agents Chemother. 54: 4235-4245.
14. Coste AT, Karababa M, Ischer F, Bille J, Sanglard D. 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell 3:1639-1652. (Pubitemid 40025121)
15. Sanglard D, Ischer F, Koymans L, Bille J. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253. (Pubitemid 28114426)
16. 5,6-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob. Agents Chemother. 56:1960-1968.
17. 5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. J. Antimicrob. Chemother. 67:2131-2138.
18. Morschhauser J, Barker KS, Liu TT, Bla BWJ, Homayouni R, Rogers PD. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3:e164. doi:10.1371/journal.ppat.0030164. (Pubitemid 350291598)
19. Sanglard D, Ischer F, Monod M, Bille J. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305. (Pubitemid 26328036)
20. Dunkel N, Blass J, Rogers PD, Morschhauser J. 2008. Mutations in the multidrug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol. 69:827-840. (Pubitemid 352033303)
21. Ferrari S, Ischer F, Calabrese D, Posteraro B, Sanguinetti M, Fadda G, Rohde B, Bauser C, Bader O, Sanglard D. 2009. Gain-of-function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog. 5:e1000268. doi:10.1371/journal.ppat.1000268.
22. Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, Morschhauser J, Rogers PD. 2012. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot. Cell 11:1289-1299.
23. Feng LJ, Wan Z, Wang XH, Li RY, Liu W. 2010. Relationship between antifungal resistance of fluconazole-resistant Candida albicans and mutations in ERG11 gene. Chin. Med. J. 123:544-548.
24. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48:568-574. (Pubitemid 38141718)
25. Geber A, Hitchcock CA, Swartz JE, Pullen FS, Marsden KE, Kwon-Chung KJ, Bennett JE. 1995. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob. Agents Chemother. 39:2708-2717.
26. Torelli R, Posteraro B, Ferrari S, La Sorda M, Fadda G, Sanglard D, Sanguinetti M. 2008. The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata. Mol. Microbiol. 68:186-201. (Pubitemid 351363785)
27. Martel CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, Rolley N, Kelly DE, Kelly SL. 2010. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob. Agents Chemother. 54:4527-4533.
28. Schubert S, Rogers PD, Morschhauser J. 2008. Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains. Antimicrob. Agents Chemother. 52:4274-4280.
29. Eddouzi J, Lohberger A, Vogne C, Manai M, Sanglard D. Identification and antifungal susceptibility of a large collection of yeast strains isolated in Tunisian Hospitals. Med. Mycol., in press.
30. Fonzi WA, Irwin MY. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728. (Pubitemid 23193572)
31. Karababa M, Coste AT, Rognon B, Bille J, Sanglard D. 2004. Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob. Agents Chemother. 48:3064-3079. (Pubitemid 38989176)
32. Cheng Q, Sanglard D, Vanhanen S, Liu H, Bombelli P, Smith A, Slabas A. 2005. Candida yeast long-chain fatty alcohol oxidase is a c-type haemoprotein and plays an important role in long chain fatty acid metabolism. Biochim. Biophys. Acta 1735:192-203. (Pubitemid 41140429)
33. Coste A, Turner V, Ischer F, Morschhauser J, Forche A, Selmecki A, Berman J, Bille J, Sanglard D. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172:2139-2156.
34. Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. 2003. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob. Agents Chemother. 47:2404-2412. (Pubitemid 36919437)
35. Alcazar-Fuoli L, Mellado E, Cuenca-Estrella M, Sanglard D. 2011. Probing the role of point mutations in the cyp51A gene from Aspergillus fumigatus in the model yeast Saccharomyces cerevisiae. Med. Mycol. 49: 276-284.
36. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
37. Vandeputte P, Pradervand S, Ischer F, Coste AT, Ferrari S, Harshman K, Sanglard D. 2012. Identification and functional characterization of Rca1, a transcription factor involved in both antifungal susceptibility and host response in Candida albicans. Eukaryot. Cell 11:916-931.
38. Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE. 1995. Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8,24(28)-dien-3β,6a-diol. Biochem. Biophys. Res. Commun. 207:910-915.
39. Hiller D, Sanglard D, Morschhäuser J. 2006. Overexpression of the MDR1gene is sufficient to confer increased resistance to toxic compounds in Candida albicans. Antimicrob. Agents Chemother. 50:1365-1371.
40. MacPherson S, Larochelle M, Turcotte B. 2006. A fungal family of transcriptional regulators: the zinc cluster proteins. Microbiol. Mol. Biol. Rev. 70:583-604. (Pubitemid 44484686)
41. Morio F, Loge C, Besse B, Hennequin C, Pape PL. 2010. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azolesusceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn. Microbiol. Infect. Dis. 66:373-384.
42. Sanglard D, Ischer F, Monod M, Bille J. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143(Pt 2):405-416. (Pubitemid 27092176)
43. Lees N, Skaggs B, Kirsch D, Bard M. 1995. Cloning of the late genes in the ergosterol biosynthetic pathway of Saccharomyces cerevisiae: a review. Lipids 30:221-226.
44. Bard M, Lees N, Turi T, Craft D, Cofrin L, Barbuch R, Koegel C, Loper J. 1993. Sterol synthesis and viability of ERG11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans. Lipids 28:963-967. (Pubitemid 23333690)
45. Martel CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, Kelly DE, Kelly SL. 2010. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14α-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrob. Agents Chemother. 54:3578-3583.
46. Mogavero S, Tavanti A, Senesi S, Rogers PD, Morschhauser J. 2011. Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1. Antimicrob. Agents Chemother. 55:2061-2066.
47. Silver PM, Oliver BG, White TC. 2004. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot. Cell 3:1391-1397. (Pubitemid 40025098)
48. MacPherson S, Akache B, Weber S, De Deken X, Raymond M, Turcotte B. 2005. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob. Agents Chemother. 49:1745-1752. (Pubitemid 40631584)
49. Sanglard D, Coste A, Ferrari S. 2009. Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res. 9:1029-1050.
50. Alvarez-Rueda N, Fleury A, Morio F, Pagniez F, Gastinel L, Le Pape P. 2011. Amino acid substitutions at the major insertion loop of Candida albicans sterol 14α-demethylase are involved in fluconazole resistance. PLoS One 6:e21239. doi:10.1371/journal.pone.0021239.
51. Jiang C, Dong D, Yu B, Cai G, Wang X, Ji Y, Peng Y. 2013. Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J. Antimicrob. Chemother. 68:778-785.
52. Vandeputte P, Larcher G, Berges T, Renier G, Chabasse D, Bouchara JP. 2005. Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob. Agents Chemother. 49:4608-4615. (Pubitemid 41552590)
53. Barchiesi F, Calabrese D, Sanglard D, Falconi Di Francesco L, Caselli F, Giannini D, Giacometti A, Gavaudan S, Scalise G. 2000. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob. Agents Chemother. 44:1578-1584. (Pubitemid 30340798)
54. Hull CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, Kelly DE, Kelly SL. 2012. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrob. Agents Chemother. 56:4223-4232.